These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 33792222)
1. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Kim M; Lee JO; Koh J; Kim TM; Lee JY; Jeon YK; Keam B; Kim DW; Lee JS; Heo DS Haematologica; 2021 Aug; 106(8):2277-2280. PubMed ID: 33792222 [No Abstract] [Full Text] [Related]
2. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987 [TBL] [Abstract][Full Text] [Related]
3. Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. Heiser RA; Cao AT; Zeng W; Ulrich M; Younan P; Anderson ME; Trueblood ES; Jonas M; Thurman R; Law CL; Gardai SJ Mol Cancer Ther; 2024 Jan; 23(1):68-83. PubMed ID: 37775098 [TBL] [Abstract][Full Text] [Related]
13. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma. Chen R; Chen B Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851 [TBL] [Abstract][Full Text] [Related]
16. [Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin]. Cai MC; Xu PP; Zhao WL Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):81-86. PubMed ID: 36987732 [No Abstract] [Full Text] [Related]
17. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. Scarisbrick JJ Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086 [TBL] [Abstract][Full Text] [Related]
18. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039 [TBL] [Abstract][Full Text] [Related]
19. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441 [TBL] [Abstract][Full Text] [Related]
20. CD30-positive malignant lymphomas: time for a change of management? Engert A Haematologica; 2013 Aug; 98(8):1165-8. PubMed ID: 23904233 [No Abstract] [Full Text] [Related] [Next] [New Search]